Join
Live feed
·
INSIDERFilingvia Quantisnow
CytomX Therapeutics Inc. logo

Chief Financial Officer Ogden Christopher was granted 101,500 shares, increasing direct ownership by 94% to 209,577 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CTMX· CytomX Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTMX (CytomX Therapeutics Inc.) and more on Quantisnow.